or Try an Advanced Search...

    Tyrosine Kinase Stocks List

    Symbol Grade Name % Change
    KRON F Kronos Bio, Inc. 2.22
    BBIO F BridgeBio Pharma, Inc. 1.04
    RLAY F Relay Therapeutics, Inc. -0.75
    ALLR F Allarity Therapeutics, Inc. 3.36
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Enzymes Fibroblast Growth Factor Receptor Protein Kinase Inhibitor Solid Tumors Tyrosine Kinase Receptors Achondroplasia Acute Myeloid Leukemia Advanced Solid Tumors Amyloid Amyloidosis Biology Biopharmaceutical Cancer Cancer Therapeutics Cardiomyopathy Clinical Development Congenital Adrenal Hyperplasia Cyclin Dependent Kinase Doxorubicin Drug Discovery

    Related ETFs - A few ETFs which own one or more of the above listed Tyrosine Kinase stocks.

    Symbol Grade Name Weight
    IDNA D iShares Genomics Immunology and Healthcare ETF 9.59
    CANC D Tema Oncology ETF 9.08
    PBE D PowerShares Dynamic Biotech & Genome 6.77
    CNCR F Loncar Cancer Immunotherapy ETF 4.77
    FBT D First Trust Amex Biotech Index Fund 4.51
    View all Tyrosine Kinase ETFs...
    Compare ETFs
    Compare CANC to FBT Compare IDNA to FBT Compare IDNA to PBE

        Tyrosine Kinase Stocks Recent News

        Date Stock Title
        Nov 20 RLAY Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
        Nov 19 BBIO BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
        Nov 19 RLAY Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
        Nov 19 BBIO The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically
        Nov 18 BBIO Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
        Nov 18 ALLR Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
        Nov 18 BBIO BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
        Nov 17 KRON Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul
        Nov 16 KRON Kronos Bio Third Quarter 2024 Earnings: Beats Expectations
        Related Industries: Biotechnology
        Related Stock Lists: Cancer Biopharmaceutical Protein Kinase Inhibitor Biotechnology Enzymes Ophthalmic Receptor Tyrosine Kinase Treatment Of Cancer Chemical Compounds Daiichi Sankyo Eye Gastrointestinal Gastrointestinal Stromal Tumor Glucocorticoids Inflammation Life Sciences Macular Degeneration Mastocytosis Medicine Non Small Cell Lung Cancer
        Tyrosine Kinase

        Tyrosine kinase is an enzyme that catalyzes the transfer of phosphate groups from ATP to tyrosine residues on proteins. It is involved in many cellular processes, including cell growth, differentiation, and migration. Tyrosine kinases are also involved in signal transduction pathways, which are important for cell communication and regulation. Mutations in tyrosine kinases can lead to cancer and other diseases.

        Browse All Tags